Large molecule therapeutics are increasingly sought-after as a potential treatment option for a variety of disease indications. Advancing these molecules from research to process development requires production of both therapeutic candidates and tool molecules, including antibody fragments, monoclonal antibodies, Fc-fusion proteins, and a diverse range of multi-specific antibody formats. Purifying large numbers of high-quality samples for developability assessments and to generate essential data supporting multiple research projects presents a significant challenge.

In this webcast, examine the use of CHT™ XT Media, a ceramic hydroxyapatite mixed-mode resin, to facilitate purification of various large molecule formats at research scale. CHT XT can serve as a rapid and efficient alternative to preparative size-exclusion chromatography and cation-exchange for aggregation removal. In addition, it can be integrated into automated multi-dimensional chromatography configurations as a final polishing step to increase purity and throughput. Furthermore, it can prevent sample loss for molecules that are prone to a split peak elution behavior on conventional cation-exchange that coincides with on-column aggregate formation.

Key Takeaways:

• CHT XT mixed-mode media streamlines purification of large molecule therapeutics, offering efficient removal of aggregation and other contaminants.

   

• The resin can mitigate risks associated with other polishing steps that can result in sample loss, low recovery, or reduced purity.